Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality, age 65+ 81% Improvement Relative Risk Mortality, age 40-64 -64% Hospitalization, age 65+ 67% Hospitalization, age 40-64 22% c19early.com/pl Arbel et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Arbel, 109,213 patient paxlovid early treatment study: 81% lower mortality [p=0.02] and 67% lower hospitalization [p<0.0001] https://c19p.org/arbel
copied to clipboard
Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
Arbel et al., Research Square, doi:10.21203/rs.3.rs-1705061/v1 (Preprint)
1 Jun 2022    Source   PDF   Share   Tweet
Retrospective 109,213 patients in Israel, 3,939 treated with nirmatrelvir, showing lower mortality and hospitalization with treatment for the subgroup of patients >65. Authors only provide subgroup results.
risk of death, 81.0% lower, HR 0.19, p = 0.02, treatment 14 of 2,504 (0.6%), control 762 of 40,315 (1.9%), adjusted per study, multivariable, Cox proportional hazards, age 65+.
risk of death, 64.0% higher, HR 1.64, p = 0.59, treatment 9 of 1,435 (0.6%), control 334 of 64,959 (0.5%), adjusted per study, multivariable, Cox proportional hazards, age 40-64.
risk of hospitalization, 67.0% lower, HR 0.33, p < 0.001, treatment 2 of 2,504 (0.1%), control 151 of 40,315 (0.4%), adjusted per study, multivariable, Cox proportional hazards, age 65+.
risk of hospitalization, 22.0% lower, HR 0.78, p = 0.48, treatment 1 of 1,435 (0.1%), control 13 of 64,959 (0.0%), adjusted per study, multivariable, Cox proportional hazards, age 40-64.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arbel et al., 6/1/2022, retrospective, Israel, Middle East, preprint, mean age 60.0, 12 authors.
Contact: ronen.arbel@gmail.com.
All Studies   All Outcomes
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit